This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Looking for a Growth Stock? 3 Reasons Why Colgate-Palmolive (CL) is a Solid Choice
by Zacks Equity Research
Colgate-Palmolive (CL) possesses solid growth attributes, which could help it handily outperform the market.
Are You Looking for a High-Growth Dividend Stock? Colgate-Palmolive (CL) Could Be a Great Choice
by Zacks Equity Research
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Colgate-Palmolive (CL) have what it takes? Let's find out.
3 Investing Facts About Required Minimum Distributions You Need to Know - June 29, 2020
by Zacks Equity Research
Like many investors, you're likely aiming to build a comfortable nest egg to ensure a comfortable retirement. Make sure you know all about what financial planners dub the accumulation and distribution phases of retirement planning.
Buy Clorox (CLX) Stock Now for Coronavirus Volatility and Beyond?
by Benjamin Rains
Clorox shares have surged 35% in 2020 to crush the S&P 500's 5% decline as its disinfectant wipes fly off the shelves during the coronavirus pandemic. With this in mind, investors might want to consider buying CLX stock as coronavirus volatility returns...
Fed Sparks Economic Concerns: Winning Investment Strategies
by Sanghamitra Saha
The Fed now expects the U.S. unemployment rate to hit 9.3% this year and sees American GDP falling by 6.5% in 2020.
Colgate-Palmolive (CL) Up 2.9% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Colgate-Palmolive (CL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is Clorox (CLX) Stock Still a Great Buy for the Eventual Coronavirus Recovery?
by Benjamin Rains
Clorox topped our quarterly earnings and revenue estimates on May 1, and the stock has jumped 12% since the end of April. Some investors might think the rally is overdone. But is Clorox still a great buy even near its new highs?
Inside the Q1 Earnings Strength of Staples ETFs and Q2 View
by Sanghamitra Saha
Staples stocks had a decent Q1 earnings season but will see negative currency translations in Q2. Plus, not all players in the sector are immune to coronavirus-led lockdowns.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Colgate (CL) Beats on Q1 Earnings and Sales, Withdraws View
by Zacks Equity Research
Colgate (CL) delivers strong first-quarter 2020 top and bottom lines, driven by strong volume growth and robust pricing, offset by unfavorable foreign currency.
Quarterly Earnings Beats for Exxon, Clorox, AbbVie & More
by Mark Vickery
Where we find our good news this hour is in quarterly earnings season, where these five big-name companies all outperformed expectations.
Colgate-Palmolive (CL) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Colgate-Palmolive (CL) delivered earnings and revenue surprises of 2.74% and 1.01%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Consumer Staples Stock Earnings for May 1: CL, CLX & EL
by Rajani Lohia
Despite the havoc created by the Coronavirus pandemic, consumer staples companies look poised for gains from spiked demand for everyday essentials.
Factors Likely to Decide Colgate's (CL) Fate in Q1 Earnings
by Zacks Equity Research
Colgate-Palmolive's (CL) first-quarter results are likely to reflect investment in brands, favorable pricing strategy and enhancement of e-commerce capabilities.
Will Newell (NWL) Retain its Positive Earnings Trend in Q1?
by Zacks Equity Research
Newell (NWL) gains from transformation efforts that enable it to improve productivity, reduce overhead costs and enhance e-commerce. It expects coronavirus effects to hurt first-quarter 2020 results.
Colgate-Palmolive (CL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Coronavirus Ruins March Retail Sales: Top & Flop ETF Areas
by Sanghamitra Saha
March retail sales saw a record decline due to the coronavirus-led economic shutdown. These ETF areas won/lost in the month.
3 Highly-Ranked Stocks to Buy for the Coronavirus Economy & the Eventual Recovery
by Benjamin Rains
On today's episode of Full Court Finance, we explore three stocks that appear to be buys at the moment and down the road when the economy eventually turns around from the coronavirus downturn...
Why Clorox (CLX) Stock is a Long-Term Buy Far Beyond the Coronavirus
by Benjamin Rains
Clorox sells disinfectant products that kill germs at home and in healthcare settings, which makes it almost tailor-made for the coronavirus economy. Better still, Clorox's portfolio is far more diverse and CLX appears to be a solid longer-term buy...
Soap & Cleaning Materials Stocks Afloat Amid Coronavirus Crisis
by Rajani Lohia
The Soap & Cleaning Materials space stands to gain from the coronavirus-led hike in demand for disinfectants and cleansing agents in the near term.
Coronavirus Hits Feb Retail Sales: Winning & Losing ETFs
by Sanghamitra Saha
If February's grim retail sales report is any guide for March, then investors can easily get an idea about what lies ahead for these specific ETFs.
Colgate's (CL) 2.3% Dividend Hike Boosts Shareholder Value
by Zacks Equity Research
Colgate (CL) hikes quarterly cash dividend to 44 cents per share from 43 cents. Its efforts regarding product innovation and in-store implementation bode well.
Why Is Colgate-Palmolive (CL) Down 2.7% Since Last Earnings Report?
by Zacks Equity Research
Colgate-Palmolive (CL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Colgate (CL) Gains From Growth Strategies, Cost Woes Persist
by Zacks Equity Research
Colgate (CL) is benefiting from innovation plans, savings program and expansion strategies. However, increased raw material costs, higher SG&A expenses and currency woes remain concerns.
Economic Data Deluge
by Zacks Equity Research
Economic Data Deluge